Opioid Receptor, Mu (OPRM1) Genotype, 1 Variant
2008767
Ordering Recommendation
Pretherapeutic identification of individuals who may require higher or lower doses of opioid drugs to achieve adequate pain control or have a better response to naltrexone for the treatment of alcohol and/or opioid dependency.
Mnemonic
OPRM1
Methodology
Polymerase Chain Reaction/High Resolution Melt Analysis
Performed
Mon, Thu
Reported
5-7 days  
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Lavender (EDTA) or pink (K2EDTA)  
Specimen Preparation
Transport 3 mL whole blood. (Min: 1 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
  
Remarks
  
Stability
Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month  
Reference Interval
By report.  
Interpretive Data
Background Information for Opioid Receptor, Mu (OPRM1) Genotype, 1 Variant:
Characteristics:
Lower sensitivity to opioid receptor agonists prescribed for pain control (e.g., morphine) and higher sensitivity to opioid receptor antagonists used in the treatment of alcohol and opioid dependency (e.g., naltrexone).
Inheritance:
Autosomal recessive.
Cause:
OPRM1 c.118A>G (p.Asn40Asp); also known as G allele.
G allele frequency:
African Americans 0.04, Caucasians 0.14, Hispanics 0.24.
Penetrance:
Drug dependent.
Clinical Sensitivity:
Unknown.
Methodology:
Polymerase Chain Reaction/High Resolution Melt Analysis.
Analytical Sensitivity and Specificity:
Greater than 99 percent.
Limitations:
Only the targeted OPRM1 mutation, c.118A>G, will be detected; additional mutations in OPRM1 or other genes will not be detected. Diagnostic errors can occur due to rare sequence variations. Genetic testing is not a substitute for clinical monitoring. Non-genetic factors may also affect opioid response.





See Compliance Statement C: www.aruplab.com/CS
Statement C: The performance characteristics of this test were validated by ARUP Laboratories. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. ARUP is authorized under Clinical Laboratory Improvement Amendments (CLIA) and by all states to perform high-complexity testing.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
 
Note
New York DOH approval pending. Call for status update.
CPT Code(s)
81479
Components
Component Test Code*Component Chart NameLOINC
2008768OPRM1 Genotype, Specimen 
2008769OPRM1 Genotype, Interpretation 
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Opioid receptor sensitivity (Opioid Receptor, Mu (OPRM1) Genotype, 1 Variant)